2903 related articles for article (PubMed ID: 28829876)
21. Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials.
Brunner-La Rocca HP; Eurlings L; Richards AM; Januzzi JL; Pfisterer ME; Dahlström U; Pinto YM; Karlström P; Erntell H; Berger R; Persson H; O'Connor CM; Moertl D; Gaggin HK; Frampton CM; Nicholls MG; Troughton RW
Eur J Heart Fail; 2015 Dec; 17(12):1252-61. PubMed ID: 26419999
[TBL] [Abstract][Full Text] [Related]
22. Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.
Felker GM; Ahmad T; Anstrom KJ; Adams KF; Cooper LS; Ezekowitz JA; Fiuzat M; Houston-Miller N; Januzzi JL; Leifer ES; Mark DB; Desvigne-Nickens P; Paynter G; Piña IL; Whellan DJ; O'Connor CM
JACC Heart Fail; 2014 Oct; 2(5):457-65. PubMed ID: 25194287
[TBL] [Abstract][Full Text] [Related]
23. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.
Ezekowitz JA; O'Connor CM; Troughton RW; Alemayehu WG; Westerhout CM; Voors AA; Butler J; Lam CSP; Ponikowski P; Emdin M; Patel MJ; Pieske B; Roessig L; Hernandez AF; Armstrong PW
JACC Heart Fail; 2020 Nov; 8(11):931-939. PubMed ID: 33039447
[TBL] [Abstract][Full Text] [Related]
24. Changes in N-terminal pro-B-type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the I-Preserve study.
Jhund PS; Anand IS; Komajda M; Claggett BL; McKelvie RS; Zile MR; Carson PE; McMurray JJ
Eur J Heart Fail; 2015 Aug; 17(8):809-17. PubMed ID: 25921853
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model.
Pufulete M; Maishman R; Dabner L; Mohiuddin S; Hollingworth W; Rogers CA; Higgins J; Dayer M; Macleod J; Purdy S; McDonagh T; Nightingale A; Williams R; Reeves BC
Health Technol Assess; 2017 Aug; 21(40):1-150. PubMed ID: 28774374
[TBL] [Abstract][Full Text] [Related]
26. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
Grewal J; McKelvie RS; Persson H; Tait P; Carlsson J; Swedberg K; Ostergren J; Lonn E
Am J Cardiol; 2008 Sep; 102(6):733-7. PubMed ID: 18773998
[TBL] [Abstract][Full Text] [Related]
27. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status.
Kristensen SL; Mogensen UM; Jhund PS; Rørth R; Anand IS; Carson PE; Desai AS; Pitt B; Pfeffer MA; Solomon SD; Zile MR; Køber L; McMurray JJV
Circ Heart Fail; 2019 Mar; 12(3):e005766. PubMed ID: 30871349
[TBL] [Abstract][Full Text] [Related]
28. Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study.
Gaggin HK; Mohammed AA; Bhardwaj A; Rehman SU; Gregory SA; Weiner RB; Baggish AL; Moore SA; Semigran MJ; Januzzi JL
J Card Fail; 2012 Aug; 18(8):626-34. PubMed ID: 22858078
[TBL] [Abstract][Full Text] [Related]
29. N-terminal pro-B-type natriuretic peptide post-discharge monitoring in the management of patients with heart failure and preserved ejection fraction - a randomized trial: The NICE study.
Pascual-Figal DA; Hernández-Vicente A; Pastor-Pérez F; Martínez-Sellés M; Solé-González E; Alvarez-García J; García-Pavía P; Varela-Román A; Sánchez PL; Delgado JF; Noguera-Velasco JA; Bayes-Genis A;
Eur J Heart Fail; 2024 Apr; 26(4):776-784. PubMed ID: 38606524
[TBL] [Abstract][Full Text] [Related]
30. Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study.
Weiner RB; Baggish AL; Chen-Tournoux A; Marshall JE; Gaggin HK; Bhardwaj A; Mohammed AA; Rehman SU; Barajas L; Barajas J; Gregory SA; Moore SA; Semigran MJ; Januzzi JL
Eur J Heart Fail; 2013 Mar; 15(3):342-51. PubMed ID: 23132825
[TBL] [Abstract][Full Text] [Related]
31. Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.
Pieske B; Wachter R; Shah SJ; Baldridge A; Szeczoedy P; Ibram G; Shi V; Zhao Z; Cowie MR;
JAMA; 2021 Nov; 326(19):1919-1929. PubMed ID: 34783839
[TBL] [Abstract][Full Text] [Related]
32. Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.
Okuyama R; Ishii J; Takahashi H; Kawai H; Muramatsu T; Harada M; Yamada A; Motoyama S; Matsui S; Naruse H; Sarai M; Hasegawa M; Watanabe E; Suzuki A; Hayashi M; Izawa H; Yuzawa Y; Ozaki Y
Heart Vessels; 2017 Jul; 32(7):880-892. PubMed ID: 28154958
[TBL] [Abstract][Full Text] [Related]
33. The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study.
Ibrahim NE; Januzzi JL
Curr Heart Fail Rep; 2018 Apr; 15(2):37-43. PubMed ID: 29468530
[TBL] [Abstract][Full Text] [Related]
34. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
[TBL] [Abstract][Full Text] [Related]
35. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction.
Januzzi JL; Rehman SU; Mohammed AA; Bhardwaj A; Barajas L; Barajas J; Kim HN; Baggish AL; Weiner RB; Chen-Tournoux A; Marshall JE; Moore SA; Carlson WD; Lewis GD; Shin J; Sullivan D; Parks K; Wang TJ; Gregory SA; Uthamalingam S; Semigran MJ
J Am Coll Cardiol; 2011 Oct; 58(18):1881-9. PubMed ID: 22018299
[TBL] [Abstract][Full Text] [Related]
36. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial.
McKelvie RS; Komajda M; McMurray J; Zile M; Ptaszynska A; Donovan M; Carson P; Massie BM;
J Card Fail; 2010 Feb; 16(2):128-34. PubMed ID: 20142024
[TBL] [Abstract][Full Text] [Related]
37. Worsening Renal Function during Management for Chronic Heart Failure with Reduced Ejection Fraction: Results From the Pro-BNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
Ibrahim NE; Gaggin HK; Rabideau DJ; Gandhi PU; Mallick A; Januzzi JL
J Card Fail; 2017 Feb; 23(2):121-130. PubMed ID: 27469482
[TBL] [Abstract][Full Text] [Related]
38. Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial.
Greene SJ; Maggioni AP; Fonarow GC; Solomon SD; Böhm M; Kandra A; Prescott MF; Reimund B; Hua TA; Lesogor A; Zannad F; Gheorghiade M;
Eur J Heart Fail; 2015 Jan; 17(1):98-108. PubMed ID: 25597870
[TBL] [Abstract][Full Text] [Related]
39. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.
Gheorghiade M; Greene SJ; Butler J; Filippatos G; Lam CS; Maggioni AP; Ponikowski P; Shah SJ; Solomon SD; Kraigher-Krainer E; Samano ET; Müller K; Roessig L; Pieske B;
JAMA; 2015 Dec; 314(21):2251-62. PubMed ID: 26547357
[TBL] [Abstract][Full Text] [Related]
40. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.
Sinning C; Kempf T; Schwarzl M; Lanfermann S; Ojeda F; Schnabel RB; Zengin E; Wild PS; Lackner KJ; Munzel T; Blankenberg S; Wollert KC; Zeller T; Westermann D
Int J Cardiol; 2017 Jan; 227():272-277. PubMed ID: 27838133
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
